Eledon Historical Balance Sheet

ELDN Stock

USD 3.35 0.06 1.76%

Trend analysis of Eledon Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 12.2 M or Total Stockholder Equity of 66.1 M provides information on Eledon Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Eledon Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Eledon Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Eledon Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eledon Pharmaceuticals is a good buy for the upcoming year.

Eledon Pharmaceuticals Inventory

1.19 Million

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

About Eledon Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Eledon Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Eledon Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Eledon Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Eledon currently owns. An asset can also be divided into two categories, current and non-current.

Eledon Pharmaceuticals Balance Sheet Chart

At this time, Eledon Pharmaceuticals' Non Current Liabilities Total is very stable compared to the past year. As of the 28th of March 2025, Other Stockholder Equity is likely to grow to about 497.3 M, while Total Assets are likely to drop about 89.9 M.

Total Assets Total Current Liabilities Property Plant And Equipment Net Accounts Payable

Total Assets

Total assets refers to the total amount of Eledon Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Eledon Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Eledon Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eledon Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents Eledon Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Eledon Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Eledon Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.At this time, Eledon Pharmaceuticals' Non Current Liabilities Total is very stable compared to the past year. As of the 28th of March 2025, Other Stockholder Equity is likely to grow to about 497.3 M, while Total Assets are likely to drop about 89.9 M.

	2022	2023	2024	2025 (projected)
Cash	56.4M	4.6M	20.5M	19.5M
Accounts Payable	2.2M	967K	5.8M	6.1M

Cash Accounts Payable

Eledon Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock Total Equity	Common Stock	Short Term Investments	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Other Assets
Total Assets		0.41	0.51	0.93	0.58	-0.65	-0.54	0.51	0.65	0.85	0.0	0.83	0.37	-0.16	0.7	0.75	-0.09	0.58	0.83	-0.2	0.32	0.22	-0.43	0.83	0.41	0.5
Other Current Liab	0.41		0.86	0.31	0.71	-0.03	-0.67	0.74	0.02	0.1	-0.11	0.69	0.69	0.2	0.51	0.6	0.29	0.71	0.69	-0.11	0.68	0.73	-0.11	0.41	0.64	-0.21
Total Current Liabilities	0.51	0.86		0.43	0.87	-0.01	-0.9	0.95	0.01	0.23	-0.09	0.81	0.9	0.16	0.58	0.85	0.27	0.87	0.81	-0.17	0.86	0.79	-0.21	0.6	0.84	-0.14
Total Stockholder Equity	0.93	0.31	0.43		0.55	-0.71	-0.44	0.41	0.71	0.8	0.2	0.76	0.25	-0.49	0.66	0.7	-0.43	0.55	0.77	-0.32	0.14	0.01	-0.53	0.77	0.26	0.52
Property Plant And Equipment Net	0.58	0.71	0.87	0.55		-0.06	-0.83	0.84	0.06	0.47	0.01	0.69	0.72	-0.02	0.66	0.87	0.09	1.0	0.7	-0.31	0.62	0.51	-0.43	0.73	0.66	-0.12
Net Debt	-0.65	-0.03	-0.01	-0.71	-0.06		-0.09	0.01	-1.0	-0.5	0.01	-0.52	0.16	0.39	-0.2	-0.16	0.37	-0.06	-0.52	-0.06	0.19	0.26	0.1	-0.35	0.15	-0.59
Retained Earnings	-0.54	-0.67	-0.9	-0.44	-0.83	-0.09		-0.86	0.09	-0.37	0.14	-0.71	-0.83	-0.17	-0.72	-0.92	-0.28	-0.83	-0.72	0.17	-0.82	-0.71	0.28	-0.68	-0.78	0.12
Accounts Payable	0.51	0.74	0.95	0.41	0.84	0.01	-0.86		-0.01	0.3	0.02	0.79	0.96	0.22	0.42	0.84	0.33	0.84	0.8	-0.3	0.88	0.79	-0.33	0.68	0.9	-0.02
Cash	0.65	0.02	0.01	0.71	0.06	-1.0	0.09	-0.01		0.5	-0.02	0.52	-0.16	-0.4	0.21	0.16	-0.38	0.06	0.51	0.06	-0.19	-0.27	-0.1	0.34	-0.15	0.59
Non Current Assets Total	0.85	0.1	0.23	0.8	0.47	-0.5	-0.37	0.3	0.5		0.07	0.53	0.14	-0.14	0.61	0.63	-0.1	0.47	0.53	-0.32	0.06	-0.03	-0.6	0.86	0.12	0.53
Non Currrent Assets Other	0.0	-0.11	-0.09	0.2	0.01	0.01	0.14	0.02	-0.02	0.07		-0.03	0.06	-0.47	-0.21	0.01	-0.48	0.01	-0.03	-0.89	-0.25	-0.29	-0.75	0.17	0.07	0.12
Cash And Short Term Investments	0.83	0.69	0.81	0.76	0.69	-0.52	-0.71	0.79	0.52	0.53	-0.03		0.72	-0.01	0.57	0.82	0.09	0.69	1.0	-0.15	0.68	0.59	-0.28	0.73	0.67	0.32
Common Stock Shares Outstanding	0.37	0.69	0.9	0.25	0.72	0.16	-0.83	0.96	-0.16	0.14	0.06	0.72		0.34	0.3	0.75	0.44	0.72	0.72	-0.29	0.94	0.87	-0.26	0.55	0.95	-0.09
Non Current Liabilities Total	-0.16	0.2	0.16	-0.49	-0.02	0.39	-0.17	0.22	-0.4	-0.14	-0.47	-0.01	0.34		-0.16	-0.04	0.99	-0.02	-0.01	0.31	0.49	0.61	0.35	-0.04	0.33	-0.2
Other Current Assets	0.7	0.51	0.58	0.66	0.66	-0.2	-0.72	0.42	0.21	0.61	-0.21	0.57	0.3	-0.16		0.75	-0.09	0.66	0.59	-0.02	0.34	0.27	-0.23	0.59	0.31	-0.07
Other Stockholder Equity	0.75	0.6	0.85	0.7	0.87	-0.16	-0.92	0.84	0.16	0.63	0.01	0.82	0.75	-0.04	0.75		0.07	0.87	0.83	-0.32	0.69	0.54	-0.49	0.86	0.69	0.16
Total Liab	-0.09	0.29	0.27	-0.43	0.09	0.37	-0.28	0.33	-0.38	-0.1	-0.48	0.09	0.44	0.99	-0.09	0.07		0.09	0.09	0.29	0.58	0.69	0.32	0.03	0.42	-0.21
Property Plant And Equipment Gross	0.58	0.71	0.87	0.55	1.0	-0.06	-0.83	0.84	0.06	0.47	0.01	0.69	0.72	-0.02	0.66	0.87	0.09		0.7	-0.31	0.62	0.51	-0.43	0.73	0.66	-0.12
Total Current Assets	0.83	0.69	0.81	0.77	0.7	-0.52	-0.72	0.8	0.51	0.53	-0.03	1.0	0.72	-0.01	0.59	0.83	0.09	0.7		-0.16	0.68	0.59	-0.29	0.73	0.67	0.31
Common Stock Total Equity	-0.2	-0.11	-0.17	-0.32	-0.31	-0.06	0.17	-0.3	0.06	-0.32	-0.89	-0.15	-0.29	0.31	-0.02	-0.32	0.29	-0.31	-0.16		0.03	0.08	0.92	-0.51	-0.26	-0.13
Common Stock	0.32	0.68	0.86	0.14	0.62	0.19	-0.82	0.88	-0.19	0.06	-0.25	0.68	0.94	0.49	0.34	0.69	0.58	0.62	0.68	0.03		0.96	0.03	0.41	0.89	-0.15
Short Term Investments	0.22	0.73	0.79	0.01	0.51	0.26	-0.71	0.79	-0.27	-0.03	-0.29	0.59	0.87	0.61	0.27	0.54	0.69	0.51	0.59	0.08	0.96		0.11	0.29	0.82	-0.23
Short Long Term Debt Total	-0.43	-0.11	-0.21	-0.53	-0.43	0.1	0.28	-0.33	-0.1	-0.6	-0.75	-0.28	-0.26	0.35	-0.23	-0.49	0.32	-0.43	-0.29	0.92	0.03	0.11		-0.72	-0.23	-0.33
Net Tangible Assets	0.83	0.41	0.6	0.77	0.73	-0.35	-0.68	0.68	0.34	0.86	0.17	0.73	0.55	-0.04	0.59	0.86	0.03	0.73	0.73	-0.51	0.41	0.29	-0.72		0.5	0.44
Current Deferred Revenue	0.41	0.64	0.84	0.26	0.66	0.15	-0.78	0.9	-0.15	0.12	0.07	0.67	0.95	0.33	0.31	0.69	0.42	0.66	0.67	-0.26	0.89	0.82	-0.23	0.5		-0.09
Other Assets	0.5	-0.21	-0.14	0.52	-0.12	-0.59	0.12	-0.02	0.59	0.53	0.12	0.32	-0.09	-0.2	-0.07	0.16	-0.21	-0.12	0.31	-0.13	-0.15	-0.23	-0.33	0.44	-0.09

Click cells to compare fundamentals

Eledon Pharmaceuticals Account Relationship Matchups

Eledon Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	197.2M	170.5M	92.8M	125.9M	177.4M	89.9M
Other Current Liab	829K	1.9M	3.5M	2.5M	5.4M	5.7M
Total Current Liabilities	2.5M	4.4M	6.5M	3.9M	11.6M	12.2M
Total Stockholder Equity	190.6M	164.0M	84.2M	83.4M	118.1M	66.1M
Property Plant And Equipment Net	138K	768K	739K	365K	926K	972.3K
Net Debt	(114.1M)	(84.1M)	(55.7M)	(4.2M)	(19.6M)	(20.6M)
Retained Earnings	(80.4M)	(114.9M)	(202.9M)	(243.2M)	(355.6M)	(337.8M)
Accounts Payable	1.4M	1.8M	2.2M	967K	5.8M	6.1M
Cash	114.2M	84.8M	56.4M	4.6M	20.5M	19.5M
Non Current Assets Total	81.6M	82.2M	33.3M	69.8M	33.7M	26.0M
Non Currrent Assets Other	383K	400K	150K	186K	363K	316.7K
Cash And Short Term Investments	114.2M	84.8M	56.4M	51.1M	140.2M	147.2M
Common Stock Shares Outstanding	1.5M	14.8M	14.3M	24.6M	485.4M	509.7M
Liabilities And Stockholders Equity	197.2M	170.5M	92.8M	125.9M	177.4M	89.9M
Non Current Liabilities Total	4.1M	2.2M	2.1M	38.6M	47.7M	50.1M
Other Current Assets	1.3M	3.5M	3.1M	5.0M	3.6M	2.2M
Other Stockholder Equity	271.0M	278.9M	287.0M	326.6M	473.6M	497.3M
Total Liab	6.6M	6.6M	8.6M	42.5M	59.3M	62.2M
Property Plant And Equipment Gross	138K	768K	739K	365K	926K	972.3K
Total Current Assets	115.6M	88.3M	59.5M	56.1M	143.7M	150.9M
Common Stock	13K	15K	14K	24K	60K	63K
Short Long Term Debt Total	144K	769K	746K	383K	954K	773.4K
Net Tangible Assets	12.6M	9.5M	109.6M	83.0M	95.4M	100.2M
Short Term Debt	288K	738K	726K	383K	314K	298.3K
Property Plant Equipment	14K	321K	138K	768K	883.2K	927.4K
Net Invested Capital	190.6M	164.0M	84.2M	83.4M	118.1M	94.0M
Net Working Capital	113.1M	83.9M	53.0M	52.2M	132.2M	138.8M
Capital Stock	13K	15K	14K	24K	60K	63K
Capital Lease Obligations	144K	769K	746K	383K	954K	608.7K

Pair Trading with Eledon Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eledon Stock

0.65

CDIOW

Cardio Diagnostics

Pair Corr

Moving against Eledon Stock

0.47	LUCD	Lucid Diagnostics	Pair Corr
0.31	WM	Waste Management	Pair Corr

The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.

The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock:

How To Invest In Eledon

Details

Is Eledon Stock a good investment?

Details

What is Eledon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.75)

Return On Assets

(0.33)

Return On Equity

(0.58)

The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eledon Historical Balance Sheet

Eledon Pharmaceuticals Inventory

1.19 Million

About Eledon Balance Sheet Analysis

Eledon Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Accounts Payable

Eledon Pharmaceuticals balance sheet Correlations

Eledon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eledon Pharmaceuticals balance sheet Accounts

Pair Trading with Eledon Pharmaceuticals

Moving together with Eledon Stock

Moving against Eledon Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Common Stock Shares Outstanding	+ 0.96	Accounts Payable
Short Term Investments	+ 0.96	Common Stock
Accounts Payable	+ 0.95	Total Current Liabilities

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.9	Total Current Liabilities
Common Stock Total Equity	- 0.89	Non Currrent Assets Other
Accounts Payable	- 0.86	Retained Earnings
Property Plant And Equipment Gross	- 0.83	Retained Earnings